GTx, Inc.

GTx, Inc. Reports First Quarter 2008 Financial Results

Published in Food and Drug Law Weekly, May 30th, 2008

GTx, Inc. (Nasdaq: GTXI) reported financial results for the first quarter of 2008. The net loss for the quarter ended March 31, 2008 was $12.7 million, compared with a net loss of $8.1 million for the same period in 2007. At March 31, 2008, GTx had cash, cash equivalents and short-term investments of $134.7 million.

"Our first quarter announcement that the toremifene 80 mg Phase III ADT clinical trial met its primary endpoint was a transformational event for GTx," said Mitchell S. Steiner, M.D., CEO of GTx. "We plan to file the New Drug Application with FDA this summer and are preparing for a launch of toremifene 80 mg in 2009. We have initiated the process for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2008-05-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry